Date: Jul 12, 2010 Source: Company Data
AntiCancer, Inc., and Cambridge Research & Instrumentation, Inc. (CRi) have agreed to settle patent litigation which has been ongoing between the two companies in the U.S. District Court for the Southern District of California since January 2007. Company presidents Robert M. Hoffman, Ph.D. (of AntiCancer) and George A. Abe (of CRi) announced the agreement today. The settlement resolves all claims between the parties. Financial terms were not disclosed.
AntiCancer, Inc. is a leader in providing animal models, cell lines, and therapeutics for imaging tumor cells in small animals. Its stock is privately held. AntiCancer is headquartered in San Diego, California, where it remains the oldest free-standing biotechnology company in the San Diego cluster. AntiCancer has subsidiaries in China, Japan, and Korea. More information about AntiCancer is available at www.anticancer.com. CRi develops and sells optical imaging systems to advance biomedical research and molecular-based drug and diagnostic development. Its stock is privately held. CRi is headquartered in Woburn, Massachusetts. More information about CRi is available at www.cri-inc.com.
